Stock INNO INNOCAN PHARMA CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Financials InnoCan Pharma Corporation

Equities

INNO

CA45783P1027

Pharmaceuticals

Market Closed - Canadian Securities Exchange
Other stock markets
 15:47:28 2024-04-26 EDT 		5-day change 1st Jan Change
0.28 CAD +1.82% Intraday chart for InnoCan Pharma Corporation +3.70% -9.68%
04-01 InnoCan Pharma Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 CI
03-25 Innocan Pharma Corporation Announces the Signing of an Agreement with the Hebrew University CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023
Capitalization 1 17.71 49.06 157.2 39.6 62.67
Enterprise Value (EV) 1 15.81 46.76 146.2 34.68 58.82
P/E ratio -4.45 x -4.28 x -14.1 x -10.5 x -12.8 x
Yield - - - - -
Capitalization / Revenue - 6,132,126,693 x 802,166,588 x 15,473,823 x 4,588,686 x
EV / Revenue - 6,132,126,405 x 802,166,532 x 15,473,821 x 4,588,686 x
EV / EBITDA -5,906,670 x -10,471,080 x -21,140,869 x -6,354,920 x -16,622,728 x
EV / FCF -18,300,682 x 16,380,320 x -21,223,270 x -6,340,166 x -87,053,562 x
FCF Yield -0% 0% -0% -0% -0%
Price to Book 12.5 x -13.7 x 17.4 x 6.19 x 15.3 x
Nbr of stocks (in thousands) 143,866 186,523 248,490 249,728 268,002
Reference price 2 0.1231 0.2630 0.6327 0.1586 0.2338
Announcement Date 20-04-08 21-03-31 22-03-31 23-03-30 24-04-01
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales - - 0.008 0.196 2.559 13.66
EBITDA - -2.998 -4.685 -7.437 -6.231 -3.77
EBIT 1 -0.3343 -3.001 -4.725 -7.48 -6.266 -3.803
Operating Margin - - -59,062.5% -3,816.33% -244.86% -27.85%
Earnings before Tax (EBT) 1 -0.3343 -3.335 -9.953 -10.09 -3.888 -4.034
Net income 1 -0.3343 -3.335 -9.953 -10.05 -3.764 -4.7
Net margin - - -124,412.5% -5,126.02% -147.09% -34.41%
EPS 2 -0.1742 -0.0276 -0.0614 -0.0447 -0.0151 -0.0183
Free Cash Flow - -0.9676 2.995 -7.408 -6.246 -0.7199
FCF margin - - 37,435.94% -3,779.66% -244.06% -5.27%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 19-05-31 20-04-08 21-03-31 22-03-31 23-03-30 24-04-01
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt - - - - - -
Net Cash position - 1.9 2.3 11 4.91 3.85
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow - -0.97 2.99 -7.41 -6.25 -0.72
ROE (net income / shareholders' equity) - -433% 907% -373% -51.1% -80.1%
ROA (Net income/ Total Assets) - -116% -85.4% -55.3% -40.1% -34.2%
Assets 1 - 2.882 11.65 18.17 9.395 13.76
Book Value Per Share 2 0.0100 0.0100 -0.0200 0.0400 0.0300 0.0200
Cash Flow per Share - 0.0100 0.0100 0.0400 0.0200 0.0100
Capex - 0.01 - 0.04 0.03 0.05
Capex / Sales - - - 20.92% 1.02% 0.34%
Announcement Date 19-05-31 20-04-08 21-03-31 22-03-31 23-03-30 24-04-01
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
INNOCAN PHARMA CORPORATION Stock InnoCan Pharma Corporation
-9.68% 57.41M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. INNO Stock
  4. Financials InnoCan Pharma Corporation